Trademark Overview
On Tuesday, July 9, 2024, a trademark application was filed for MULTIGEN with the United States Patent and Trademark Office. The USPTO has given the MULTIGEN trademark a serial number of 79404951. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, September 26, 2024. This trademark is owned by Confo Therapeutics N.V.. The MULTIGEN trademark is filed in the Advertising, Business and Retail Services, Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical and veterinary preparations for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteins, namely, small molecules and antibodies for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; veterinary products for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases.
Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management.
Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs).
Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and ...
